ClinicalTrials.gg

Program

orticumab

Also written as “MLDL1278A” and “Orticumab”.

Its studies are mostly in Psoriasis · Acute Coronary Syndrome · Atherosclerosis, led by 3 companies.

Furthest: phase 2, since Feb 16, 20214 company-led studies, 1 open or runningNext primary completion: Feb 8, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abcentra21 open or runningphase 2since Feb 16, 2021Feb 16, 2021Feb 8, 2027phase 2 · NCT06927739
BioInvent International AB10 open or runningphase 1since Nov 22, 2011Nov 22, 2011none ahead
Hoffmann-La Roche10 open or runningphase 2since Dec 10, 2010Dec 10, 2010none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 10, 2010First study: phase 2 study in AtherosclerosisNew to Hoffmann-La RocheHoffmann-La Roche · NCT01258907 · 147 enrolled · United States, Canada
  2. Nov 22, 2011BioInvent International AB's first study: phase 1 study in HealthyNew to BioInvent International ABBioInvent International AB · NCT01486823 · 22 enrolled · United Kingdom
  3. Feb 16, 2021Abcentra's first study: phase 2 study in PsoriasisNew to AbcentraAbcentra · NCT04776629 · 77 enrolled · United States
  4. Mar 25, 2025Phase 2 study in Acute Coronary SyndromeAbcentra · NCT06927739 · 240 planned · United States, Czechia, Hungary and more

Ahead

  1. Feb 8, 2027Primary completion: phase 2 study in Acute Coronary SyndromeAbcentra · NCT06927739

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06927739Acute Coronary Syndrome · United States, Czechia, Hungary and more2RecruitingAbcentraFeb 8, 2027240
NCT04776629Psoriasis · United States2CompletedAbcentraNov 11, 202277
NCT01486823Healthy · United Kingdom1CompletedBioInvent International ABJul 201222
NCT01258907Atherosclerosis · United States, Canada2CompletedHoffmann-La RocheJul 2012147

How it is read

Names in the registry

  • “MLDL1278A”, 4 entries
  • “Orticumab”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.